Condensed Consolidated Statement of Cash Flows	3 Months Ended
	Jun. 30, 2015 USD ($)
Cash flows from operating activities:
Net loss	$ (28,058,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation	22,282,000
Depreciation and amortization	1,000
Deferred tax assets	(182,000)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(25,000)
Accounts payable	228,000
Due to Roivant Sciences Ltd. and Roivant Sciences, Inc. for amounts paid on behalf of the Company	(344,000)
Accrued liabilities	1,311,000
Income tax payable	252,000
Net cash used in operating activities	(4,535,000)
Cash flows from investing activities:
Purchase of property, plant and equipment	(7,000)
Net cash used in investing activities	(7,000)
Cash flows from financing activities:
Cash proceeds from issuance of common shares in initial public offering, net of underwriting discount	336,893,000
Initial public offering costs paid	(1,684,000)
Cash capital contribution from Roivant Sciences Ltd.	750,000
Repayment of amounts due to Roivant Sciences Ltd. and Roivant Sciences, Inc. for amounts paid on behalf of the Company	(627,000)
Due to Roivant Sciences Ltd. and Roivant Sciences, Inc. for amounts paid on behalf of the Company	279,000
Net cash provided by financing activities	335,611,000
Net change in cash	331,069,000
Cash-end of period	331,069,000
Non-cash financing activities:
Unpaid initial public offering costs	707,000
Supplemental disclosure of cash paid:
Taxes	$ 5,000